Ep. 175 - Acelyrin IPO, Alzheimer's Data & Digital Endpoints

BioCentury This Week

English - May 09, 2023 00:00 - 25 minutes - 17.5 MB - ★★★★★ - 11 ratings
Science biotech biopharma pharmaceutical research investment dealmaking Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Ep. 174 - EC Pharma Law, ALS Biomarker, Astellas' Iveric Deal

Next Episode: Ep. 176 - Bio€quity Europe 2023 Preview: Crafting a European Playbook for Success

Acelyrin last week parlayed a late-stage asset for hidradenitis suppurativa and veteran leadership into one of biotech’s largest-ever NASDAQ IPOs. On the latest BioCentury This Week podcast, BioCentury’s editors discussed how Acelyrin generated outsized demand for its offering and assessed Alzheimer’s data for Eli Lilly's donanemab, the promise and challenges of digital endpoints and takeaways from the latest BioCentury Show, which featured incoming FogPharma CEO Mathai Mammen in conversation with Editor in Chief Simone Fishburn. This week’s podcast is sponsored by Cancer Research Horizons.